Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 8

recruiting
3 972
countries
28
conditions
2 103

1 070 trials match your criteria

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate

Comparing AZD5335 with mirvetuximab soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:AZD5335

Glioma

Recruiting

A study of ulixertinib, tovorafenib, and vinblastine sulfate for children with progressive, relapsed, or refractory low-grade glioma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Tovorafenib

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1

A study to compare glofitamab against a drug combination for patients with relapsed or refractory mantle cell lymphoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab

Hidradenitis

Recruiting

A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:SAR445399

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib

A study to compare the effectiveness of rituximab and a placebo in patients with interstitial lung disease associated with rheumatoid arthritis

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab

Study of the safety and use of the Extroducer infusion catheter system for delivering gemcitabine to patients with unresectable locally advanced pancreatic cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Carbidopa

Study of the effects of stopping elranatamab and teclistamab treatment in patients with multiple myeloma who have had a significant response to therapy.

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.